Management of anti-allogeneic antibody elimination by apheresis in living donor liver transplantation

Naoki Kawagishi, Ikuo Takeda, Shigehito Miyagi, Kazushige Satoh, Yorihiro Akamatsu, Satoshi Sekiguchi, Keisei Fujimori, Toshinobu Sato, Susumu Satomi

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)


In this study, we report on the indications and efficacy of the elimination of antiallogeneic antibodies in living donor liver transplant recipients. Seven patients incompatible with the ABO-blood type were subjected to apheresis before transplantation. The procedure resulted in titers being decreased to less than a score of 8. After transplantation, apheresis was also performed in 6 cases and continuous hemodiafiltration in 1 case. In addition, three out of 11 ABO-blood type incompatible recipients were administered anti-CD20 antibody (rituximab). Two crossmatch positive patients were subjected to apheresis before transplantation, and in these cases the titers were reduced to less than a score of 2. Moreover, these two patients had no acute rejections after transplantation. We concluded that apheresis is effective for preventing acute rejection induced by pre-existing anti-A and/or anti-B antibodies, as well as antidonor specific antibodies, but is not effective in some patients who had accelerated humoral rejection.

Original languageEnglish
Pages (from-to)319-324
Number of pages6
JournalTherapeutic Apheresis and Dialysis
Issue number5
Publication statusPublished - 2007 Oct


  • ABO incompatible
  • Apheresis
  • Crossmatch positive
  • Living donor liver transplantation
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Nephrology


Dive into the research topics of 'Management of anti-allogeneic antibody elimination by apheresis in living donor liver transplantation'. Together they form a unique fingerprint.

Cite this